Please use this identifier to cite or link to this item:
http://hdl.handle.net/1942/42034
Title: | 1-or 3-Month DAPT in Patients With HBR With or Without Oral Anticoagulant Therapy After PCI | Authors: | Valgimigli, Marco Spirito, Alessandro Sartori, Samantha Angiolillo, Dominick J. VRANCKX, Pascal Hernandez, Jose M. de la Torre Krucoff, Mitchell W. Bangalore, Sripal Bhatt, Deepak L. Campo, Gianluca Cao, Davide Chehab, Bassem M. Choi, James W. Feng, Yihan Ge, Junbo Hermiller, James Kunadian, Vijay Lupo, Sydney Makkar, Raj R. Maksoud, Aziz Neumann, Franz-Josef Picon, Hector Saito, Shigeru Sardella, Gennaro Thiele, Holger Toelg, Ralph Varenne, Olivier Vogel, Birgit Zhou, Yujie Windecker, Stephan Mehran, Roxana |
Issue Date: | 2023 | Publisher: | ELSEVIER SCIENCE INC | Source: | JACC-Cardiovascular Interventions, 16 (20) , p. 2498 -2510 | Abstract: | BACKGROUND The optimal duration of dual antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI) in patients on long-term oral anticoagulation (OAC) therapy is still uncertain. OBJECTIVES The aim of this analysis was to assess the effects of 1-vs 3-month DAPT in patients with and those without concomitant OAC included in the XIENCE Short DAPT program. METHODS The XIENCE Short DAPT program enrolled patients with high bleeding risk who underwent successful PCI with a cobalt-chromium everolimus-eluting stent. DAPT was discontinued at 1 or 3 months in patients free from ischemic events and adherent to treatment. The effect of 1-vs 3-month DAPT was compared in patients with and those without OAC using propensity score stratification. The primary endpoint was all-cause death or any myocardial infarction (MI). The key secondary endpoint was Bleeding Academic Research Consortium (BARC) types 2 to 5 bleeding. Outcomes were assessed from 1 to 12 months after index PCI. RESULTS Among 3,364 event-free patients, 1,462 (43%) were on OAC. Among OAC patients, the risk for death or MI was similar between 1-and 3-month DAPT (7.4% vs 8.8%; adjusted HR: 0.74; 95% CI: 0.49-1.11; P = 0.139), whereas BARC types 2 to 5 bleeding was lower with 1-month DAPT (adjusted HR: 0.71; 95% CI: 0.51-0.99; P = 0.046). These effects were consistent in patients with and those without OAC (P for interaction = NS). CONCLUSIONS Between 1 and 12 months after PCI, 1-month compared with 3-month DAPT was associated with similar rates of all-cause death or MI and a reduced rate of BARC types 2 to 5 bleeding, irrespective of OAC treatment. (J Am Coll Cardiol Intv 2023;16:2498-2510) (c) 2023 by the American College of Cardiology Foundation. | Notes: | Mehran, R (corresponding author), Icahn Sch Med Mt Sinai, 1 Gustave L Levy Pl,Box 1030, New York, NY 10029 USA. roxana.mehran@mountsinai.org |
Keywords: | KEY WORDS dual antiplatelet therapy;everolimus-eluting stent(s);high bleeding risk;oral anticoagulant therapy;percutaneous coronary intervention | Document URI: | http://hdl.handle.net/1942/42034 | ISSN: | 1936-8798 | e-ISSN: | 1876-7605 | DOI: | 10.1016/j.jcin.2023.08.014 | ISI #: | 001116471300001 | Category: | A1 | Type: | Journal Contribution |
Appears in Collections: | Research publications |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
ACFrOgB99fYcjyosScAq6YgHajoI_AoWwLWApdMSclXAE9__-VoaOapT0ec31Mu8_7tqFWuA8cyC1TJRl6d84wnTK1Lo5DhRlYqIQqytMxjP8Ur0pcqidGteoVr_bFOdW5FXcV_XeH1FLlI0Nf02.pdf | Peer-reviewed author version | 1.69 MB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.